Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2012-11-12 Capital/Financing Update
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Sobi to list bond loan on NASDAQ OMX Stockholm and publishes prospectus
Capital/Financing Update Classification · 95% confidence The document announces that Sobi has issued a bond loan and has applied for its listing on NASDAQ OMX Stockholm, stating that the prospectus has been prepared and is now available. The text explicitly mentions the preparation and availability of a 'prospectus' related to a financing activity (bond loan issuance). Since the document is short (1694 chars) and its primary function is to announce the publication/availability of the prospectus related to a financing event, it fits the description of a Report Publication Announcement (RPA) or a Capital/Financing Update (CAP). Given the focus is on the listing and the availability of the prospectus for the bond loan, 'CAP' (Capital/Financing Update) is highly relevant, but the structure strongly suggests an announcement about the release of a document (the prospectus). However, since the core event is the financing (bond loan), and the document is an announcement *about* that financing and the associated prospectus, 'CAP' is a strong candidate. Let's re-evaluate against the definitions. It is not a full financial report (10-K, IR), nor a dividend notice (DIV). It is directly about a financing activity (issuing a bond loan). Therefore, Capital/Financing Update (CAP) is the most precise fit for the underlying corporate action being announced, even though it mentions the prospectus availability. If the document were only about the prospectus release without mentioning the bond issuance details, RPA would be better. Since it details the bond issuance and listing application, CAP is chosen.
2012-11-12 English
Sobi noterar obligationslån på NASDAQ OMX Stockholm och offentliggör prospekt
Capital/Financing Update Classification · 95% confidence The document is a short announcement dated November 12, 2012, from Swedish Orphan Biovitrum (Sobi) regarding the listing of its previously issued bond loan (obligationslån) on NASDAQ OMX Stockholm and the publication of the associated prospectus, which was approved by the Swedish Financial Supervisory Authority (Finansinspektionen). The text explicitly states that the prospectus is now available on the company's website. Since this is an announcement about the publication/availability of a financial document (the prospectus) rather than the full report itself, and it concerns a financing/capital activity (issuing a bond loan), it fits best under Capital/Financing Update (CAP) or potentially Report Publication Announcement (RPA). Given the core subject is the bond issuance and listing, CAP is the most specific fit for the underlying event. However, the document's immediate function is announcing the availability of the prospectus. Since the event is a financing activity (issuing a bond loan), 'CAP' (Capital/Financing Update) is the primary classification for the substance of the news. The length is short, suggesting an announcement rather than the full prospectus itself. I will classify it as CAP as it details a financing event (bond issuance and listing).
2012-11-12 Swedish
BIOGEN IDEC AND SOBI ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY INVESTIGATING LONG-LASTING RECOMBINANT FACTOR VIII FC FUSION PROTEIN IN HEMOPHILIA A
Earnings Release Classification · 98% confidence The document is a press release dated October 31, 2012, announcing positive top-line results from a Phase 3 clinical study (A-LONG) for a new drug candidate (rFVIIIFc) in Hemophilia A. It details efficacy data, safety profiles, plans for regulatory submission (BLA to US FDA in H1 2013), and mentions an associated webcast. This content structure—announcing key results immediately followed by detailed data summaries and future regulatory/presentation plans—is characteristic of an Earnings Release (ER) or a specific clinical trial result announcement. Since it focuses purely on the financial/operational outcome of R&D (clinical trial results) rather than a comprehensive quarterly/annual financial statement (IR or 10-K), and it is an initial announcement of results, the most appropriate classification is Earnings Release (ER). It is not a full transcript (CT), a formal annual report (10-K), or just a notice of a report being published (RPA). FY 2012
2012-10-31 English
BIOGEN IDEC OCH SOBI MEDDELAR POSITIVA RESULTAT FRÅN FAS III STUDIEN AVSEENDE LÅNGVERKANDE REKOMBINANT FAKTOR VIII FC FUSIONSPROTEIN FÖR BEHANDLING AV HEMOFILI A
Regulatory Filings Classification · 95% confidence The document is a press release written in Swedish announcing positive Phase III study results (A-LONG study) for a new long-acting recombinant Factor VIII Fc fusion protein for Hemophilia A treatment. It details clinical outcomes, mentions plans to file for FDA registration in H1 2013, and includes quotes from management. This content structure—announcing clinical trial results and future regulatory steps—is characteristic of an Earnings Release (ER) or a general press release regarding operational/clinical progress. Since it is not a full financial report (10-K/IR) or a transcript (CT), and it focuses on key results rather than being a mere announcement of a report's publication (RPA), the most fitting category for a significant clinical/operational update that often accompanies or precedes earnings is 'Earnings Release' (ER), as these announcements frequently contain the most material non-financial news. Alternatively, given the focus on clinical trial data, it could be seen as a specialized announcement, but ER is the best fit among the provided options for a major operational/data release.
2012-10-31 Swedish
Interim / Quarterly Report 2012
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period January-September 2012, published by Sobi. It contains comprehensive financial statements, including income statements, balance sheets, cash flow analysis, and detailed management commentary on product performance and regional revenue. It is not an announcement of a report, but the report itself, containing substantive financial data for a period shorter than a full fiscal year. 9M 2012
2012-10-30 Swedish
Interim / Quarterly Report 2012
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report, January - September 2012' and contains comprehensive financial statements, including income statements, balance sheet data, and detailed management analysis of business performance for the third quarter and the nine-month period. It is not a mere announcement or certification, but the actual financial report for an interim period, fitting the definition of an Interim/Quarterly Report (IR). 9M 2012
2012-10-30 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.